Adicet bio highlights adi-001 expansion, persistence and pharmacodynamic profile from ongoing phase 1 study at the 65th american society of hematology (ash) annual meeting

Redwood city, calif. & boston--(business wire)--adicet bio, inc. (nasdaq: acet), a clinical stage biotechnology company discovering and developing allogeneic gamma delta t cell therapies for cancer, today announced that an abstract outlining pk and pd profiling data from the company's ongoing phase 1 study of adi-001 for the potential treatment of relapsed or refractory aggressive b-cell nhl was made available as part of the 65th ash annual meeting, being held december 9-12, 2023 in san diego,.
ACET Ratings Summary
ACET Quant Ranking